Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab versus placebo for prevention of postoperative Crohn's disease recurrence
2010-018431-18Phase 3Completed
- Sponsor
- Janssen Biologics B.V.
- Start
- Jun 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing REMICADE with Placebo (2 arms). Primary endpoint: Clinical recurrence of Crohn's disease prior to or at Week 76. Started Jun 2010; status: completed.
02
Drugs
infliximab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2010-018431-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018431-18.